If this is the case, when you factor in the (at least) two people recruited into the NETs liver P1 in Australia, PVCT has almost doubled the amount of liver patients since 2017 (maybe even 2018) alone.
We went from having around 18 patients over the span of around 7 years to close to 30 in the last year and some change.
Several people on these boards have always wanted PVCT to move towards liver trials based on the tremendous results we saw from the liver trials. Looks like they're getting their wish. There was a lot of frustration that PVCT appeared to be letting a potential blockbuster and (possibly) fast path to approval slide by not pushing forward with liver treatments. PHR appears to be thinking the same way as those that felt we need to push this area.
GI cancers as a group are responsible for more deaths than any other disease type. This is a tremendous market to break into.
Also, yesterday I read a stat that said the CR rate in pd-1/pd-l1 therapy across approved solid tumor indications is only 5%. Just throwing that out there. I think a lot of people think it's higher than it really is.
Hombre's posts have me feeling all tingly inside. :)